KALA BIO, INC. Gain (Loss) on Extinguishment of Debt
KALA BIO, INC. (KALA) reported Gain (Loss) on Extinguishment of Debt of $5.79 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-15.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2026-04-15
- KALA BIO, INC. gain (loss) on extinguishment of debt for the quarter ending 2022-12-31 was $0.00.
- KALA BIO, INC. gain (loss) on extinguishment of debt for the quarter ending 2022-09-30 was -$2.58M.
- KALA BIO, INC. gain (loss) on extinguishment of debt for the quarter ending 2021-12-31 was $0.00.
- KALA BIO, INC. gain (loss) on extinguishment of debt for the quarter ending 2021-09-30 was $0.00.
- KALA BIO, INC. gain (loss) on extinguishment of debt for fiscal 2025 was $5.79M.
- KALA BIO, INC. gain (loss) on extinguishment of debt for fiscal 2022 was -$2.58M.
- KALA BIO, INC. gain (loss) on extinguishment of debt for fiscal 2021 was -$5.39M.
- KALA BIO, INC. gain (loss) on extinguishment of debt for fiscal 2018 was -$390.00K.
| Period end | Gain (Loss) on Extinguishment of Debt | Gain (Loss) on Extinguishment of Debt 3 month | Gain (Loss) on Extinguishment of Debt 6 month | Gain (Loss) on Extinguishment of Debt 9 month | Gain (Loss) on Extinguishment of Debt 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $5.79M 10-K · filed 2026-04-15 | ||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | -$2.58M derived: sum of 2 quarters · filed 2026-04-15 | -$2.58M 10-K · filed 2026-04-15 | ||
| 2022-09-30 | -$2.58M 10-Q · filed 2023-11-13 | -$2.58M 10-Q · filed 2023-11-13 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | $0.00 derived: sum of 2 quarters · filed 2023-03-03 | -$5.39M derived: sum of 3 quarters · filed 2023-03-03 | -$5.39M 10-K · filed 2023-03-03 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$5.39M derived: sum of 2 quarters · filed 2022-11-08 | -$5.39M 10-Q · filed 2022-11-08 | ||
| 2021-06-30 | -$5.39M 10-Q · filed 2022-08-11 | -$5.39M 10-Q · filed 2022-08-11 | |||
| 2021-05-04 | -$5.39M 10-Q · filed 2021-08-05 | ||||
| 2018-12-31 | -$390.00K 10-K · filed 2020-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |